Press Release Summary:
Featuring lower-red wavelength, VivoTagÂ® 645 is optimized for labeling of biomolecules in range of imaging application for both in-vitro and in-vivo research areas. Product is optimized for system compatibility, brightness, biocompatibility, and stability in biological environments. Areas of particular use include labeling and imaging of proteins, antibodies, and small molecules.
Original Press Release:
VisEn Launches New VivoTag® 645 Fluorescence Molecular Imaging Label
Extends VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Expanded Imaging Applications in Research and Drug Development
BEDFORD, Mass. -- VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new VivoTag® 645 red fluorescent dye for optimized labeling of biomolecules in a broad range of in vitro and in vivo research applications.
The new VivoTag 645 represents VisEn's first agent offering in the lower-red wavelengths, enabling optimized and integrated imaging applications in both in vivo and in vitro research areas. The VivoTag 645 is specifically designed for efficient and robust labeling of biomolecules, and is optimized for broad in vitro and in vivo imaging performance, including system compatibility, superior brightness, biocompatibility and stability in biological environments.
"Our new VivoTag 645 represents an important evolution in our fluorescent imaging agent product line," said Kirtland Poss, President and CEO of VisEn Medical. "This new label is designed to be well-suited for applications both in vitro and in vivo research and we look forward to working closely with our customers in continually advancing these integrated research areas."
The new VivoTag 645 is particularly well suited for labeling and imaging of proteins, antibodies, and small molecules in a range of research areas. The fluorescence wavelength is matched for biological imaging applications on in vitro and in vivo fluorescence systems, including advanced microscopes, high content imaging and flow cytometry systems. It is also optimized for use with VisEn's fluorescence tomography FMT(TM) imaging systems which also have expanded wavelength capabilities to enable quantitative imaging of up to four channels and four different biomarkers of interest in vivo.
VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts. VisEn offers over 35 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense®, IntegriSense(TM), AngioSense(TM), OsteoSense®, MMPSense(TM), GastroSense(TM), ReninSenseTM, Annexin-VivoTM, and the FAST(TM) line of imaging agents including Cat K FAST(TM) and Cat B FAST(TM). VisEn also offers specialized lines of agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes and its NanoSpark® nanoparticles for customized fluorescence agent labeling. They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including in vitro, cell, tissue and in vivo imaging applications.
All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and other cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking preclinical research into clinical medicine.
About VisEn Medical Inc.
VisEn's in vivo fluorescence imaging technologies, including its RED Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific preclinical and clinical research areas. Additional information can be found at www.visenmedical.com.
CONTACT: Robert Sandler, SVP, Marketing of VisEn Medical Inc., office: +1-647-350-1881, Cell: 416.274.8166, email@example.com